CEO SUMMARY: A disruptive force that involves precision medicine, pharmaceutical companies, and venture capital investors is poised to reshape the clinical laboratory industry. Genetic knowledge makes it possible to match cancer drugs to specific mutations. Pharma companies and professional investors recognize that control of diagnostic technologies and companion diagnostic tests enable them to gain better access […]
Why Pharma, Private Equity Want to Reshape Lab Industry
It’s not about the lab test...but the expensive drug indicated by the test
- By Joseph Burns
- > From the Volume XXV No. 5 - March 26, 2018 Issue
- Tags: Anatomic pathology, anatomic pathology services, association for clinical biochemistry, biopsies, biopsy, blood test for cancer, blood tests, clinical biochemistry, clinical lab, clinical lab testing, clinical laboratories, Clinical Laboratory, clinical laboratory industry, clinical laboratory market, clinical laboratory scientists, clinical laboratory test, clinical laboratory testing, clinical labs, clinical testing, companion diagnostic, companion diagnostic test, Companion diagnostics, diagnostic testing, Diagnostic tests, executive war college, gene sequencing, generation sequencing, genetic test, genetic testing, genetic testing reimbursement, genetic tests, genomics, in vitro diagnostics, lab industry, lab test, lab testing, lab testing companies, lab tests, laboratories, laboratory diagnostics, laboratory industry, laboratory instrumentation, laboratory managers, laboratory medicine, laboratory scientists, laboratory test, laboratory testing, laboratory tests, managed care, mass spectrometry, medical laboratories, next generation sequencing, next generation sequencing panels, pathologists, pathology groups, pathology services, test for cancer, tests for cancer, the clinical laboratory, the laboratory
